TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

News & Events

4.15.19

TG Therapeutics Announces Orphan Drug Designation for Umbralisib from the US FDA for the Treatment of Marginal Zone Lymhpoma

4.1.19

TG Therapeutics Reports Positive Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with MZL at the 2019 AACR

Quick Links